TF and ovarian cancer: As summarized in our previous reviews [64,69], TF expression was detected on the cancer cells in patients with a broad range of solid cancers, including non-triple breast cancer (non-TNBC) (81–100%), primary melanoma (95%) and metastatic melanoma (100%), lung cancer (40–80%), ovarian cancer (84%), pancreatic cancer (53–90%), colorectal cancer (57–100%), hepatocellular carcinoma (63–100%), primary and metastatic prostate cancer (60–78%), and glioma (47–75%).